What is the clinical evidence from this study?

Study design: Review. Population: Coronary artery stenting. Intervention: Aspirin and clopidogrel hyporesponsiveness.

What question did this study set out to answer?

Examine the prevalence, clinical impact, and underlying mechanisms of hyporesponsiveness and resistance to dual antiplatelet therapy in patients receiving coronary artery stents.

November 1, 2009Vascular Health and Risk ManagementOpen Access

Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting

View Full Paper

Ask AI

Bookmark

Key result

Up to 25% of patients with acute myocardial infarction undergoing percutaneous coronary intervention exhibit hyporesponsiveness or resistance to clopidogrel, predisposing them to recurrent events.

Population

Patients undergoing coronary artery stenting receiving dual antiplatelet therapy, including those with acute…

Design

Review

Authors

RSRakesh SharmaSouthport College RReddyCentral Leather Research Institute VSVibhuti SinghRiverside Methodist Hospital

Discussion

Member takes

Implication

Clopidogrel hyporesponsiveness warrants clinical awareness in AMI-PCI; leaves open whether testing or alternatives improve outcomes.

Key Points

Examine the prevalence, clinical impact, and underlying mechanisms of hyporesponsiveness and resistance to dual antiplatelet therapy in patients receiving coronary artery stents.
Synthesized evidence from clinical trials and guidelines regarding dual antiplatelet regimens with aspirin and clopidogrel in percutaneous coronary intervention.
Evaluated patient-level and pharmacologic determinants of antiplatelet resistance, including compliance, comorbidities, genetics, and concomitant medications.
Up to 25% of patients with acute myocardial infarction undergoing percutaneous coronary intervention exhibit hyporesponsiveness or resistance to clopidogrel.
Impaired antiplatelet response predisposes patients to subacute stent thrombosis, late stent thrombosis, and recurrent acute coronary syndrome.
Variable responsiveness stems primarily from genetic mutations, patient noncompliance, clinical comorbidities, and drug-drug interactions.

Structured PICO

Population

Patients undergoing coronary artery stenting receiving dual antiplatelet therapy, including those with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI)

Exposure

Dual antiplatelet therapy (aspirin and clopidogrel)

This review highlights the clinical importance and prevalence of aspirin and clopidogrel hyporesponsiveness in patients with coronary stents, which may predispose them to stent thrombosis and recurrent ischemic events.

Cite This Study

Sharma et al. (2009) conducted a review in Coronary artery stenting. Aspirin and clopidogrel hyporesponsiveness was evaluated. Up to 25% of patients with acute myocardial infarction undergoing percutaneous coronary intervention exhibit hyporesponsiveness or resistance to clopidogrel, predisposing them to recurrent events.

synapsesocial.com/papers/6a85abcb36b936d5b31099ba https://doi.org/10.2147/vhrm.s6787

Topics

Coronary artery disease Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider